Celiac disease diagnosis in clinical practice: ESPGHAN quality of care survey from 129 pediatric hospitals across 28 countries

. 2025 Sep ; 81 (3) : 606-617. [epub] 20250707

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid40621676

Grantová podpora
ESPGHAN
Ludwig Maximilians Universität Munich

OBJECTIVES: European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines recommend first-line serology for suspected celiac disease (CeD), measuring only transglutaminase antibodies (TGA-immunoglobulin A [IgA]) plus total IgA. If TGA-IgA is ≥10 times the normal value, pediatric gastroenterologists (pedGI) may diagnose CeD without biopsies if autoantibodies against endomysial antibodies (EMA-IgA) are positive in a 2nd blood sample. This Quality-of-Care (QoC) project benchmarked diagnostic workup in clinical practice using ESPGHAN CeD guidelines as reference. METHODS: A pseudonymized survey on CeD practices was sent to 141 hospitals within the ESPGHAN QoC-network in 28 countries. RESULTS: Questionnaires were completed by 129/141 (91.5%) hospitals, with 121 (94%) having pedGI staff. As reasons conflicting with good QoC for CeD in their setting, responders assumed knowledge deficits among the public (57%), primary care providers (64%), non-GI physicians (16%), and pedGIs (0%). For initial testing, 66% of physicians ordered only total IgA and TGA-IgA, 7% did not use this combination, and 29% ordered additional serology (TGA-IgG, EMA, antibodies against deaminated gliadin peptide, or native gliadin). Regarding conflicting results for TGA-IgA and histopathology in IgA-sufficient children, 61% incorrectly classified negative TGA-IgA with Marsh 2 and 57% with Marsh 3 lesions as "potential CeD," while 49% excluded CeD in the case of villous atrophy and negative TGA-IgA. Routine practice did not align with the ESPGHAN recommendations regarding performance of duodenal biopsies (27%), EMA-testing (34%), and diagnosis of CeD in IgA-deficient children (32%). CONCLUSIONS: We identified areas for improving QoC regarding both effectiveness and efficacy, in pediatric patients with suspected CeD, and consequently developed easy-to-use tools to improve guideline implementation.

Zobrazit více v PubMed

Husby S, Koletzko S, Korponay‐Szabó IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54(1):136‐160. PubMed

Husby S, Koletzko S, Korponay‐Szabó I, et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition guidelines for diagnosing coeliac disease 2020. J Pediatr Gastroenterol Nutr. 2020;70(1):141‐156. PubMed

Werkstetter KJ, Korponay‐Szabó IR, Popp A, et al. Accuracy in diagnosis of celiac disease without biopsies in clinical practice. Gastroenterology. 2017;153(4):924‐935. PubMed

Arguelles‐Grande C, Tennyson CA, Lewis SK, Green PHR, Bhagat G. Variability in small bowel histopathology reporting between different pathology practice settings: impact on the diagnosis of coeliac disease. J Clin Pathol. 2012;65(3):242‐247. PubMed

Mubarak A, Nikkels P, Houwen R, Ten Kate F. Reproducibility of the histological diagnosis of celiac disease. Scand J Gastroenterol. 2011;46(9):1065‐1073. PubMed

Popp A, Arvola T, Taavela J, et al. Nonbiopsy approach for celiac disease is accurate when using exact duodenal histomorphometry: prospective study in 2 countries. J Clin Gastroenterol. 2021;55(3):227‐232. PubMed

Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62(1):43‐52. PubMed PMC

Litwin A, Le Thi TG, Pancheva R, et al. Anthropometric assessment: ESPGHAN quality of care survey from paediatric hospitals in 28 European countries. J Pediatr Gastroenterol Nutr. 2024;78(4):936‐947. PubMed

Lacaille F, Nicastro E, Czubkowski P, et al. Awareness, referral and age at Kasai surgery for biliary atresia in Europe: a survey of the Quality‐of‐Care Task Force of ESPGHAN. J Pediatr Gastroenterol Nutr. 2024;78(6):1374‐1382. PubMed

Riznik P, De Leo L, Dolinsek J, et al. The knowledge about celiac disease among healthcare professionals and patients in central Europe. J Pediatr Gastroenterol Nutr. 2021;72(4):552‐557. PubMed

Khalil H, de Moel‐Mandel C, Verma D, et al. Characteristics of quality improvement projects in health services: a systematic scoping review. J Evid Based Med. 2025;18(1):e12670. PubMed PMC

Gould MJ, Brill H, Marcon MA, Munn NJ, Walsh CM. In screening for celiac disease, deamidated gliadin rarely predicts disease when tissue transglutaminase is normal. J Pediatr Gastroenterol Nutr. 2019;68(1):20‐25. PubMed

Dios A, Srinivasan B, Gyimesi J, et al. Changes in non‐deamidated versus deamidated epitope targeting and disease prediction during the antibody response to gliadin and transglutaminase of infants at risk for celiac disease. Int J Mol Sci. 2022;23(5):2498. PubMed PMC

Popp A, Laurikka P, Czika D, Kurppa K. The role of gluten challenge in the diagnosis of celiac disease: a review. Expert Rev Gastroenterol Hepatol. 2023;17(7):691‐700. PubMed

Irvine AJ, Chey WD, Ford AC. Screening for celiac disease in irritable bowel syndrome: an updated systematic review and meta‐analysis. Am J Gastroenterol. 2017;112(1):65‐76. PubMed

Rosén A, Sandström O, Carlsson A, et al. Usefulness of symptoms to screen for celiac disease. Pediatrics. 2014;133(2):211‐218. PubMed

Agardh D, Lee HS, Kurppa K, et al. Clinical features of celiac disease: a prospective birth cohort. Pediatrics. 2015;135(4):627‐634. PubMed PMC

Egner W, Shrimpton A, Sargur R, Patel D, Swallow K. ESPGHAN guidance on coeliac disease 2012: multiples of ULN for decision making do not harmonise assay performance across centres. J Pediatr Gastroenterol Nutr. 2012;55(6):733‐735. PubMed

Backhouse A, Ogunlayi F. Quality improvement into practice. BMJ. 2020;368:m865. PubMed PMC

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...